NeuroScientific readies stem cell supply boost for bowel disease trials
AI Summary
NeuroScientific Biopharmaceuticals is transferring stem cell production for its StemSmart therapy to Q-Gen in Brisbane to scale up supply for upcoming Crohn's disease clinical trials. The move represents a significant step in advancing stem cell-based treatments for bowel disease.
NeuroScientific Biopharmaceuticals has begun transferring the production of stem cells for its StemSmart therapy to Q-Gen in Brisbane, ahead of Crohn’s disease clinical trials.